Acer Drug Patent Portfolio
Acer owns 1 orange book drug protected by 3 US patents Given below is the list of Acer's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11154521 | Palatable compositions including sodium phenylbutyrate and uses thereof | 17 Oct, 2036 | Active |
| US11202767 | Methods of treating urea cycle disorders and maple syrup urine disease | 17 Oct, 2036 | Active |
| US11433041 | Palatable compositions including sodium phenylbutyrate and uses thereof | 17 Oct, 2036 | Active |
Latest Legal Activities on Acer's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Acer.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 02 Apr, 2024 | US11154521 |
|
Email Notification
Critical
| 02 Apr, 2024 | US11433041 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 02 Apr, 2024 | US11202767 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 02 Apr, 2024 | US11433041 |
|
Recordation of Patent Grant Mailed
Critical
| 06 Sep, 2022 | US11433041 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 06 Sep, 2022 | US11433041 |
|
Email Notification
Critical
| 18 Aug, 2022 | US11433041 |
|
Issue Notification Mailed
Critical
| 17 Aug, 2022 | US11433041 |
|
Application Is Considered Ready for Issue
Critical
| 04 Aug, 2022 | US11433041 |
| Dispatch to FDC | 04 Aug, 2022 | US11433041 |
|
Issue Fee Payment Received
Critical
| 26 Jul, 2022 | US11433041 |
|
Issue Fee Payment Verified
Critical
| 26 Jul, 2022 | US11433041 |
|
Email Notification
Critical
| 20 Jul, 2022 | US11433041 |
|
Electronic Review
Critical
| 20 Jul, 2022 | US11433041 |
|
Mail Notice of Allowance
Critical
| 20 Jul, 2022 | US11433041 |
Acer's Family Patents
Acer drugs have patent protection in a total of 20 countries. It's US patent count contributes only to 24.1% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Acer Drug List
Given below is the complete list of Acer's drugs and the patents protecting them.
1. Olpruva
Olpruva is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11154521 | Palatable compositions including sodium phenylbutyrate and uses thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US11202767 | Methods of treating urea cycle disorders and maple syrup urine disease |
17 Oct, 2036
(11 years from now)
| Active |
| US11433041 | Palatable compositions including sodium phenylbutyrate and uses thereof |
17 Oct, 2036
(11 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Olpruva's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List